88IV - Public company info - Shanghai MicroPort MedBot (Group) Co. Ltd. - H Shares

Input the stock code or the company name

Search

Financial Ratios

Shanghai MicroPort MedBot (Group) Co. Ltd. - H Shares, 02252.HK - Company Profile
Chairman	Sun Hongbin
Share Issued (share)	947,000,000
Par Currency	Renminbi
Par Value	1.0
Industry	-
Corporate Profile	Business Summary: Founded in 2015, The group is a surgical robot company dedicated to designing, developing and commercializing surgical robots to assist surgeons in performing complex surgical procedures. Performance for the year: The group recorded net losses of RMB69.8 million, RMB209.3 million, RMB49.0 million and RMB242.6 million for the years ended December 31, 2019 and 2020 and for the six months ended June 30, 2020 and 2021. Business Review The group is a globally top-tier surgical robot company dedicated to designing, developing and commercializing surgical robots to assist surgeons in performing complex surgical procedures. The group is the only company in the industry worldwide with a product portfolio covering the five major and fastgrowing surgical specialties of laparoscopic, orthopedic, panvascular, natural orifice and percutaneous surgical procedures, according to Frost & Sullivan. the group’s flagship products, Toumai® (圖邁®) Laparoscopic Surgical Robot, DFVision® (蜻蜓眼®) 3D Electronic Laparoscope and Honghu (鴻鵠®) Orthopedic Surgical Robot, have all been admitted to the NMPA’s innovative medical device special review and approval procedure (known as the “Green Path”). Toumai and Honghu are at the registration approval stage, and DFVision has recently received NMPA approval. the group may not be able to successfully develop and market Toumai, Honghu and DFVision as planned, even if they are commercialized, it is uncertain that they will achieve market success. Surgical robots belong to a technically sophisticated and clinically and commercially valuable niche in the global medical devices industry, according to Frost & Sullivan. With greater precision, consistency and control, surgical robots help surgeons overcome human limitations and eliminate impediments in conventional surgical and interventional tools and techniques, reducing burdens on surgeons and delivering better clinical outcomes for patients. For example, for a successful joint replacement, minimizing alignment deviation of the implant is critical. An experienced surgeon operating manually can manage to contain the deviation to three to ten degrees; with robotic assistance, the deviation could be less than one degree. Compared with conventional minimally invasive surgery, or MIS, or traditional open surgery, robot-assisted MIS can achieve higher success rates, smaller wounds, less bleeding and faster recovery. Robot-assisted surgery, or RAS, is increasingly integrated into clinical practice as a cutting-edge complement to, and in more and more cases substitution for, conventional surgery. China has a large, fast-growing and under-penetrated surgical robot market. To date, surgical robots have very low market penetration in China in the two major application areas of laparoscopic and orthopedic surgeries (especially, in the latter case, the majority field of joint replacements). According to Frost & Sullivan, only 189 laparoscopic and 17 joint replacement surgical robots were installed in China as of December 31, 2020, and approximately 0.5% and less than 0.1% of laparoscopic and joint replacement surgeries, respectively, were robot-assisted in China in 2020. In contrast, 3,727 laparoscopic and 1,060 joint replacement surgical robots were installed in the United States as of the same date, with a penetration rate in terms of surgeries performed of 13.3% and 7.6%, respectively, in the same year, according to Frost & Sullivan. Even though the PRC surgical robot industry had a late start, it is expected to grow rapidly. According to Frost & Sullivan, the numbers of laparoscopic and joint replacement surgical robots installed in China by the end of 2026 are expected to be more than 10 and almost 50 times, respectively, the level as of the end of 2020. As the installation base grows and the number of RAS continues to rise, revenue source for surgical robot developers will also diversify. Non-robot sales revenue is expected to increase significantly, as more disposables are consumed and must be replenished and hospitals pay more for services in training and maintenance. As a result of these factors, the PRC surgical robot market is expected to expand from US$0.4 billion in 2020 to US$3.8 billion in 2026, representing a CAGR of 44.3%, while the global market is expected to expand from US$8.3 billion in 2020 to US$33.6 billion in 2026, representing a CAGR of 26.2%. Surgical robotics, from a technology perspective, is an advanced intersection of multiple disciplines. Since the group’s founding, the group have focused on five foundation technologies that must interact well together to make the hardware and software of a surgical robot work: robot ontology, control algorithms, electrical engineering, image-based navigation and precision imaging. the group believe that this focus is fundamental to the group’s product development capability. As a dedicated surgical robot specialist, the group also possess strong industrial operation capabilities covering the full cycle of surgical robot development from research and development, clinical trial and registration to supply chain management and marketing. Through in-house development and international collaboration, the group have built a portfolio with one approved product and eight product candidates at various stages of development, including two candidates in the NMPA registration application stage and six candidates in preclinical studies. Prospects: The group plan to pursue the following strategies: • advance products to commercialization and promote surgical robot penetration in China; • continue to expand product portfolio to build a multi-specialty surgical platform; • explore next-generation technologies to expand the applications of surgical robots; and • continue to implement the group’s global strategy.

Information from the financial statements of listed companies

88iv | Home | Login

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer

Copyright (C) 2024

Suntek Computer Systems Limited.

All rights reserved